ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Primary prevention of melanoma

Primary prevention of melanoma
Literature review current through: May 2024.
This topic last updated: Aug 15, 2023.

INTRODUCTION — Melanoma is a worldwide public health concern [1-3]. At least two-thirds of melanoma in populations with lightly pigmented skin worldwide may be attributed to ultraviolet (UV) radiation exposure from both natural and artificial sources [4]. Based upon this and other data implicating UV light as a risk factor for melanoma, reducing exposure to UV radiation from sunbathing and indoor tanning and increasing the use of sun protection has been advocated as a method to reduce the incidence of this malignancy [4,5]. Based on findings from SunSmart, an Australian skin cancer prevention program, the United States Centers for Disease Control and Prevention (CDC) estimated that a comprehensive national skin cancer prevention program focused on the avoidance of UV radiation exposure from sunbathing and indoor tanning could avert 230,000 melanoma cases and USD $2.7 billion in initial year treatment costs from 2020 to 2030 [6].

The observed decline in the incidence of invasive melanoma in the state of Queensland, Australia, among males and females under the age of 40 years from the period of 1995 to 2014 may be the result of sun awareness campaigns implemented in Australia on a national scale [7,8]. A similar reduction in melanoma incidence in younger males and females (age ≤45) was observed in the United States from the period of 2005 to 2014 [9]. Whether this reduction is related to increased sun protection behaviors, decreased intentional tanning, or reduced use of tanning beds among adolescents and young adults remains unclear [9,10].

Interventions that may be relevant to the primary prevention of melanoma will be reviewed here. Screening and risk factors for melanoma are discussed separately. (See "Screening for melanoma in adults and adolescents" and "Melanoma: Epidemiology and risk factors".)

ULTRAVIOLET RADIATION — Ultraviolet (UV) radiation is a known carcinogen [11]. Although a direct causal relationship between UV radiation and melanoma has not been demonstrated in humans, there is strong evidence in support of this relationship:

Epidemiologic studies have found that the risk of melanoma is higher among people with lightly pigmented skin who have increased sensitivity to sunlight [5]. In the United States, the incidence of melanoma is at least 20 times greater in White persons than in Black persons, and the highest incidence of melanoma worldwide occurs in Queensland, Australia, a subtropical region with a predominantly Celtic population [12]. (See "Melanoma: Epidemiology and risk factors", section on 'Geographic and ethnic variation'.)

A study aimed at quantifying the global population attributable fraction of melanomas due to UV radiation estimated that 168,000 new melanoma cases in 2012 were attributed to excess exposure to UV radiation, representing approximately 76 percent of all melanoma cases worldwide [13]. The global burden was higher in men than in women (95,000 attributable cases; 81.3 percent of all melanomas and 73,000; 69.4 percent, respectively). The World Health Organization (WHO) data estimated that excessive UV radiation exposure caused approximately 325,000 melanomas and 57,000 premature melanoma-related deaths in the year 2020 [14].

Among families predisposed to melanoma because of genetic mutations, the incidence of melanoma is 21-fold higher for individuals born after 1959 compared with those born before 1900, presumably due to an interaction between increased sun exposure and the predisposing gene mutation [15]. (See "Inherited susceptibility to melanoma".)

In the laboratory, melanocytic lesions, including melanoma, can be induced in human skin grafted onto mice after exposure to ultraviolet B (UVB) radiation, with or without an initiating carcinogen [16].

Other data implicate ultraviolet A (UVA) radiation as well as UVB as contributors to melanoma development. Psoriasis patients treated over long periods with a combination of UVA and oral psoralen (PUVA) had a significant increase in melanoma incidence [17,18]. (See "Melanoma: Epidemiology and risk factors", section on 'Psoralen plus ultraviolet A therapy'.)

Several systematic reviews and meta-analyses of case-control studies found an approximately 20 percent increase of melanoma risk among ever users of indoor tanning devices compared with nonusers [19-21]. The risk was higher for individuals reporting first use of sunbeds at a young age (before age 35) and for those with high exposure (≥10 sessions in lifetime). (See 'Tanning bed use' below and "Melanoma: Epidemiology and risk factors", section on 'Indoor tanning'.)

One population-based cohort study using data from the Norwegian Women and Cancer Study and including more than 140,000 women followed up for a mean of 14 years found that the risk of melanoma was increased by 25 percent among women reporting ever use of indoor tanning versus never use and was higher for those who initiated indoor tanning use before the age of 30 years [22]. The risk increased with increasing duration of use (≥10 years) and cumulative number of indoor tanning sessions (relative risk 1.61, 95% CI 1.27-2.05 for the highest quartile of cumulative number of sessions).

The exact pathways through which UV radiation can cause melanoma are incompletely understood. Two different, "divergent" epigenetic pathways that can result in cutaneous melanoma are suggested by epidemiologic population-based data [23]. Individuals with an inherently low propensity for melanocyte proliferation may require chronic sun exposure to drive clonal expansion. In contrast, those with a high propensity for melanocyte proliferation (characterized by high nevus count) may require less solar exposure to stimulate carcinogenesis [23]. (See "Melanoma: Epidemiology and risk factors", section on 'Common (typical) nevi'.)

Unlike keratinocytes, which undergo apoptosis (programmed cell death) when severely damaged by UV radiation, damaged melanocytes tend to be preserved [24]. This may be related to an effort by the body to continue to produce melanin, which has a photoprotective function in the skin [5]. The result, however, is that severely damaged melanocytes that are at risk for incomplete deoxyribonucleic acid (DNA) repair and subsequent mutation are preserved. UVB radiation (290 to 320 nm) causes the majority of DNA damage in the epidermis. However, UVA may also be important in the pathogenesis of melanoma [25]. (See "Melanoma: Epidemiology and risk factors", section on 'Ultraviolet radiation'.)

The pattern and timing of exposure to sunlight appear to be important for melanoma development. In contrast to nonmelanoma skin cancers (particularly squamous cell carcinoma), which are associated with cumulative sun exposure and occur most frequently in areas maximally exposed to the sun (ie, the face, back of hands, and forearms), most melanomas are associated with intense, intermittent sun exposure and tend to occur in areas exposed to the sun sporadically (eg, the back, lower legs) [26,27].

Exposure in childhood seems particularly important; a history of five or more severe sunburns in adolescence more than doubles the risk of developing melanoma [28]. Furthermore, the incidence of melanoma is increased among people who migrated from northern to more equatorial latitudes but only among immigrants who were children at the time of migration [29,30]. (See "Melanoma: Epidemiology and risk factors", section on 'Ultraviolet radiation'.)

SUN PROTECTION — The classification of ultraviolet (UV) radiation as carcinogenic to humans and a risk factor for melanoma and other skin cancers is used to support recommendations for sun protection [11]. Since people with darkly pigmented skin have significantly lower risk of UV radiation-induced skin cancer compared with those with lightly pigmented skin, sun protection recommendations may differ according to skin phenotype [31-33].

Sun protection behaviors include the use of broad-spectrum sunscreen with a sun protection factor (SPF) of 15 for everyday use and at least SPF 30 for intense sun exposure; wearing hats, sunglasses, and sun-protective clothing; reducing sun exposure; seeking shade during midday hours (10 AM to 4 PM); and avoiding indoor tanning bed use [34]. (See "Selection of sunscreen and sun-protective measures".)

Sunscreen — Individuals at increased risk of melanoma and individuals highly exposed to sunlight should thoroughly apply a broad-spectrum sunscreen (with an SPF of 15 for daily use and at least an SPF of 30 for intense sun exposure) before going out during daylight hours. Because of inconsistent application, the American Academy of Dermatology recommends the use of a broad-spectrum sunscreen with an SPF of at least 30 during sun exposure.

Efficacy – A systematic review for the US Preventive Services Task Force (USPSTF) in 2018 noted that although interventions focused on increasing sun protection behavior (eg, reduced sun exposure, sunscreen use, use of protective clothing, avoidance of indoor tanning) were associated with a moderate increase of sun protection behaviors in both adults and children, there was no consistent association between these interventions and reduced sunburn frequency, nevus count, or skin cancer incidence over one to three years of follow-up [35]. However, data from a follow-up study of a community-based, randomized trial in Queensland, Australia, a Norwegian population-based cohort study, and an Australian case-control study support the use of sunscreen products [36]:

In the Australian trial, 1621 participants were randomly assigned to an intervention group (unlimited supply of SPF 16 sunscreen provided and participants instructed to engage in daily sunscreen use) or a discretionary sunscreen group (participants used their own sunscreen at their own discretion) [36]. Ten years after the conclusion of the four-year trial, participants in the intervention group had developed 50 percent fewer primary melanomas compared with the control group (11 versus 22 melanomas, hazard ratio [HR] 0.50, 95% CI 0.24-1.02). The reduction was even greater for invasive melanomas: 3 melanomas occurred in the intervention group versus 11 in the control group (HR 0.27, 95% CI 0.08-0.97), corresponding to a risk reduction of 73 percent. Young and middle-aged adult participants in the intervention group were also 24 percent less likely to show findings of skin photoaging. This study provides strong evidence that the regular use of sunscreen reduces the incidence of melanoma in high-risk populations. In addition, in the same trial the rates of squamous cell carcinomas were decreased by nearly 40 percent during the entire follow-up period (rate ratio 0.62, 95% CI 0.38-0.99) [37].

A prospective population-based cohort study using data from the Norwegian Women and Cancer Study and including nearly 144,000 women aged 40 to 75 years followed up for a mean of 11 years found that the risk of melanoma was reduced by approximately 30 percent (HR 0.67, 95% CI 0.53-0.83) among women using SPF ≥15 sunscreen on at least one occasion compared with nonusers or those consistently using SPF <15 [38]. The estimated population attributable fraction (ie, the proportion of preventable melanomas) associated with SPF ≥15 sunscreen use was 18 percent. Of note, in this study, sunscreen users were more likely to be in the youngest age groups; live in areas with high ambient UV radiation; have lightly pigmented skin; and report more sunburns, sunbathing vacations, and indoor tanning, suggesting that the results might underestimate the protective impact of sunscreen use in this population.

An Australian case-control study including 603 melanoma cases and 1088 controls aged 18 to 39 years examined the association between sunscreen use during childhood and lifetime sunscreen use and risk of melanoma before the age of 40 years [39]. In a multivariate analysis, self-reported childhood sunscreen use and lifetime sunscreen use were both associated with a lower risk of melanoma (odds ratio [OR] for the highest versus the lowest tertile 0.6, 95% CI 0.42-0.87 and OR 0.65, 95% CI 0.45-0.93, respectively), after adjusting for age, sex, ethnicity, education, family history, nevus density, sun bed use, blistering sunburns, total sun exposure, and pigmentation score.

Labeling, use, and safety – Labeling and regulations, proper use, and safety of sunscreens are discussed separately. (See "Selection of sunscreen and sun-protective measures".)

Other measures — In addition to use of sunscreen products, other approaches may also be useful to decrease exposure to UV light, including:

Wearing clothes – Tightly woven fabrics and dark colors confer the highest UV protection. In addition, sun-protective clothes with designed ultraviolet protection factor (UPF) ranging from 15 to 50 are commercially available and can also be worn while swimming. Since sunscreen may not be applied as thoroughly or often as needed, sun-protective clothing is an effective alternative. (See "Selection of sunscreen and sun-protective measures", section on 'Photoprotective clothing'.)

Using special window glass and films – Common window glass provides a variable degree of ultraviolet B (UVB) protection. Developments in the glass industry have resulted in the introduction of additional filters for ultraviolet A (UVA) and infrared radiation [40]. Window films that can be applied to side windows of cars are also commercially available. These films should be compliant with state regulations in the United States or national regulations in other countries.

Using sunscreen-containing cosmetics – Cosmetics and moisturizers for daily use that contain broad-spectrum sunscreens with SPF ≥15 may improve the compliance to photoprotection [41].

In the United States, the Skin Cancer Foundation has developed a list of products, including cosmetics, moisturizers, clothes and laundry additives, sunglasses, and window protection, that can provide sun protection.

Sun protection and nevi — The presence of atypical nevi or high numbers of common nevi has been associated with increased risk for melanoma. Although sun-protective measures in children have been linked with the development of fewer nevi [42,43], it remains unclear whether sun protection can reduce the risk for melanoma through this pathway [44]. (See "Melanoma: Epidemiology and risk factors", section on 'Common (typical) nevi' and "Melanoma: Epidemiology and risk factors", section on 'Atypical nevi'.)

The following studies support the effect of sun protection on reductions in nevi count:

Sunscreen use has been shown to modestly attenuate the development of new moles in young children. In a randomized trial, White schoolchildren were randomly assigned to receive either SPF 30 broad-spectrum sunscreen (with instructions to apply it if sun exposure was expected to last 30 minutes or longer) or to no intervention [43]. Children in the sunscreen group developed fewer nevi over a three-year period (median count 24 versus 28, without sunscreen). The use of sunscreen was especially beneficial for freckled children in the intervention group. These children developed 30 to 40 percent fewer nevi than those in the control group.

At least two studies suggest that the use of a physical barrier (clothing) to prevent sun exposure may be of value for reducing the number of nevi. In one report of 12-year-old children who had been followed for more than six years, those who covered their backs all of the time had fewer new nevi than children who covered their backs less than 70 percent of the time [45].

Another study found that children who wore more clothing during holidays in sunny climates developed fewer nevi [46]. Multivariate analysis in this study did not demonstrate a benefit from the use of sunscreen.

Additional studies are necessary to determine the relationship between sun protection, nevi count, and risk of melanoma.

General guidelines — Several guidelines have been developed by scientific and specialty groups for protection from exposure to the sun [47-53]. The National Council on Skin Cancer Prevention, which is comprised of more than 40 skin cancer organizations and foundations in the United States, provides comprehensive information on skin cancer prevention that can be summarized as follows [54-56]:

Avoid sun burning, intentional tanning, and using tanning beds.

Wear sun-protective clothing, a wide-brimmed hat, and sunglasses. Seek shade.

Use extra caution near water, snow, and sand.

Get vitamin D safely through food and vitamin D supplements.

Choose a sunscreen that offers an SPF of 30 or higher, is water resistant, and provides broad-spectrum coverage (protects against UVA and UVB rays).

Apply sunscreen approximately 15 minutes before going outside.

Reapply sunscreen every two hours or after swimming or sweating, according to the product labeling.

Apply a generous amount.

The 2014 Surgeon General's Call to Action to Prevent Skin Cancer presents the following five strategic goals to support skin cancer prevention in the United States:

Increase opportunities for sun protection in outdoor settings

Provide individuals with the information they need to make informed, healthy choices about UV radiation exposure

Promote policies that advance the national goal of preventing skin cancer

Reduce harms from indoor tanning

Strengthen research, surveillance, monitoring, and evaluation related to skin cancer prevention

Status of sun protection — Participation in sun-protective measures has varied over time and with population demographics. Examples of data on sunburn and use of sun protection include the following:

In a United States cross-sectional study using a nationally representative sample of over 31,000 adults from the 2015 National Health Interview Survey (NHIS)-Cancer Control Supplement, 34 percent of participants experienced sunburn in 2015 [57]. The most frequently used sun protection behaviors were staying in the shade (37 percent) and using sunscreen (32 percent), followed by wearing long clothing to the ankles (28 percent).

In a large population-based study using data from the Norwegian Women and Cancer Study and including nearly 149,000 women aged 41 to 75 years, 87 percent reported sunscreen use during bathing vacations in southern latitudes [58]. From 1997 to 2007, the overall sunscreen use increased, although this was not accompanied by a decrease in the sunburn rate, with 39 percent of women reporting at least one sunburn in the previous year in 1997 and 46 percent in 2007.

More than 28,000 adults participated in the 2005 NHIS and were asked questions regarding sun protection behaviors and sunburns in the past year. Sun protection practices were weakest among youngest adults, persons residing in the Midwest, males, non-Hispanic White persons, those who were less educated, smokers, risky drinkers, and individuals that had skin that was less sun sensitive [59]. A 2010 analysis of the NHIS data on nearly 25,000 adult Americans found an overall sunburn rate of 37 percent in the past year, with highest rates among youngest adults of 18 to 29 years (52 percent) [60]. Rates of ≥44 percent were found among individuals who repeatedly burn or freckle after two weeks in the sun, White persons, indoor tanners, and those with a family history of melanoma.

In a series of more than 10,000 children of nurses from the Nurses' Health Study, only 34 percent of children aged 11 to 18 were using sunscreen, and 83 percent had at least one sunburn during the previous summer [61].

Observational studies have noted deficits in shade seeking and covering up among all age groups [62]. Protective practices appear to be more prevalent at the beach or on vacation than in other outdoor recreation [63]. Parents/caregivers are more likely to protect their children than themselves, although they often do not provide adequate protection for their children. One randomized trial that investigated the impact of mother education on sun protection for their children found that, taken together, 22 and 54 percent of children in the intervention and control groups, respectively, experienced a sunburn or tan during their first and second summers of life [64]. Likewise, a study of Swedish toddlers found that 20 percent had been severely sunburned at least once before their first birthday [65]. Persons with lightly pigmented skin, higher education, more knowledge, a greater fear of skin cancer, females, and those who know someone with skin cancer generally practice more preventive habits.

Perceived social norms appear especially important among adolescents and young adults. Positive attitudes toward tanning (ie, healthy, attractive) predict a lower use of sun protection [66]. Young teens' practice of sun protection tends to modestly decrease as peer pressure and fashion concerns start to influence their behavior. In a prospective study involving 360 fifth-grade children, 50 percent of students reported "often or always" use of sunscreen when outside for at least six hours in the summer [67]. At the follow-up evaluation three years later, this proportion dropped to 25 percent. At the same time, more children reported "liking a tan" and spending time in the sun to get a tan.

Vitamin D deficiency — Strict sun protection can increase the risk for vitamin D deficiency. Oral vitamin D supplementation is a safe, well-tolerated, and inexpensive alternative to achieve adequate vitamin D levels [68-70]. (See "Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment" and "Vitamin D insufficiency and deficiency in children and adolescents".)

TANNING BED USE — The working group of the International Agency for Research on Cancer concluded that tanning bed use in youth was associated with skin cancer and documented a 75 percent increase in melanoma for those who first used tanning beds in their twenties or teen years [71]. Based upon these findings, the working group concluded that minors and young adults should avoid the use of tanning devices and supported restricting access to artificial tanning facilities for individuals under the age of 18 [72].

Increased risk for melanoma has also been detected in individuals who begin tanning in mid-adulthood [73]. A population-based, case-control study including 681 patients with melanoma and 654 matched controls younger than 50 years found that women who had ever tanned indoors had a two- to sixfold increased risk of melanoma compared with women who had never tanned indoors, with the highest risk observed among those who were younger than 30 years at diagnosis [74]. In all age groups, the risk was consistently increased for women who started tanning indoors before age 25 years and for those who reported >10 lifetime tanning sessions.

Indoor tanning ban for minors In Europe, individuals under the age of 18 years are banned from using tanning beds in France, Spain, Belgium, Germany, the United Kingdom, Denmark, Finland, Iceland, Norway, Sweden, and Lithuania [75]. In Canada, tanning beds are banned for those under the age of 18 in Ontario, Quebec, and British Columbia and under the age of 19 in Nova Scotia [76]. In 2008, a joint Australian and New Zealand solarium standard banned the use of sun tanning units for persons under 18 years and for all persons with skin type I [77]. From January 2015, tanning beds have been banned in the Australian Capital Territory, New South Wales, Queensland, South Australia, Tasmania, and Victoria. A similar ban was introduced in Brazil in 2009.

In the United States, indoor tanning is banned for those under 18 in California, Connecticut, Delaware, the District of Columbia, Hawaii, Illinois, Kansas, Louisiana, Maine, Massachusetts, Minnesota, Nevada, New Hampshire, New York, North Carolina, Ohio, Oklahoma, Oregon, Rhode Island, Texas, Utah, Vermont, Washington, and West Virginia; in many other states, permission from parents/legal guardians is required for minors [78]. Studies aimed at assessing the tanning facility compliance to state laws banning indoor tanning use before the age of 18 years found that approximately 80 percent of tanning facilities are compliant [79,80].

In May 2014, the US Food and Drug Administration (FDA) issued an order requiring that sunlamp products used in tanning salons carry a visible boxed warning that states that sunlamp products should not be used on persons under the age of 18 years [81].

Addiction to tanning – Tanning bed users have reported relaxation [82], pain relief [83,84], and improved mood [85] as motivation for continuing this practice, and there is increasing evidence that biochemical addiction to tanning can occur [86-89]. In a survey of 3874 high school adolescents, 7 percent met the criteria for tanning addiction [90]. In multivariable analysis, tanning addiction had a weak association with problematic substance use and psychologic symptoms, such as depressive symptoms, panic disorder symptoms, and obsessive-compulsive disorder symptoms. However, further studies are necessary to determine the relationship between tanning and psychiatric disorders and the best approach to patients who exhibit signs of a tanning addiction. In the interim, clinicians should remain cognizant that psychologic factors may play a role in the reluctance or inability of some patients to stop tanning.

The mechanism for an addiction to tanning is unconfirmed. It has been proposed that ultraviolet (UV)-induced production of pro-opiomelanocortin products, including beta endorphins, may be a contributing factor. This theory was supported by the findings of a small randomized trial in which opioid blockade with naltrexone was associated with a reduced preference of UV exposure among frequent tanners [91]. Administration of naltrexone also led to withdrawal symptoms in four out of eight frequent tanners, while no infrequent tanners experienced withdrawal-like symptoms. However, the relationship between tanning bed exposure and opioid production remains controversial [92].

CHEMOPREVENTION — Chemoprevention (also called therapeutic prevention) is defined as the use of natural or synthetic agents to delay, reverse, suppress, or prevent premalignant lesions from progressing to invasive cancer and has been evaluated in melanoma and other skin cancers as a means of primary prevention [93-95]. Various phytochemicals, vitamins, minerals, and anti-inflammatory, antioxidant, and targeted agents are being studied, though none has been proven to prevent melanoma in clinical trials to date [96].

Vitamin D — Sun exposure is necessary for the synthesis of 25-hydroxyvitamin D in the skin. This intermediate metabolite is transformed to its biologically active form under conditions of physiologic demand for calcium and phosphorus. The potential health benefits of vitamin D continue to be explored as the incidence and survival of major internal cancers is known to improve significantly with decreasing latitudes in the United States [97]. The antiproliferative and proapoptotic effects of active vitamin D (ie, 1,25-dihydroxyvitamin D) may be a factor in the association of vitamin D with lower risk for some malignancies. (See "Overview of cancer prevention", section on 'Vitamin D'.)

Serum levels of vitamin D — An effect of vitamin D on melanoma pathogenesis was suggested by a case control study of 500 melanoma patients in which sun exposure, as measured by solar elastosis, was associated with increased survival [98]. However, serum vitamin D levels were not assessed in this study, and vitamin D levels are unlikely to be the only reason for this observation, particularly given "diverging" ultraviolet (UV) radiation-associated, phenotypic, and genetic pathways of melanoma development [23]. A 2014 meta-analysis of 20 observational studies including 1420 melanoma patients did not find an association between serum levels of vitamin D and risk of melanoma [99].

Dietary vitamin D — Studies investigating the impact of dietary vitamin D on the risk of melanoma have shown conflicting results:

Although in vitro and in vivo mouse studies have suggested a protective effect of vitamin D on melanoma [100-105], a prospective cohort study involving 68,611 patients found no association between vitamin D intake and the occurrence of melanoma [106]. An earlier case-control study found no association of melanoma risk with total vitamin D intake [107].

At least two studies of dietary vitamin D and melanoma risk have resulted in other conclusions. A case-control study of more than 1000 subjects identified a significant reduction of melanoma risk for individuals with high vitamin D intake [108]. Conversely, a large prospective study reported an increased risk of melanoma associated with cod liver oil intake (a source of vitamin D) among women but not men [109].

A 2014 meta-analysis of 20 observational studies including 1420 melanoma patients did not find an association between dietary intake of vitamin D and risk of melanoma [99]. The pooled relative risk for the highest versus lowest quintile of vitamin D intake was 0.86 (95% CI 0.63-1.13).

Calcium plus vitamin D supplementation did not reduce the overall incidence of melanoma or nonmelanoma skin cancer (NMSC) in postmenopausal women in the Women's Health Initiative (WHI) (hazard ratio [HR] 0.86, 95% CI 0.64-1.16) [110]. However, in a subgroup analysis of participants who reported a history of NMSC, women in the vitamin D and calcium group had 57 percent fewer melanomas than women in the placebo group (HR 0.43, 95% CI 0.21-0.90). This finding suggests a role for either vitamin D or calcium, or their combination, in reducing the incidence of melanoma in a high-risk group of postmenopausal women.

Nonsteroidal anti-inflammatory agents — Nonsteroidal anti-inflammatory agents (NSAIDs) have been suggested as having chemopreventive effects against melanoma. However, observational studies of different medications and in different populations have provided inconsistent evidence [111].

Several case-control studies have found a protective effect of acetylsalicylic acid (ASA) and other NSAIDs [112-114]. The melanoma risk reduction ranged from 13 to 50 percent, depending upon the frequency and duration of use. The risk reduction was greatest for long-term, continuous use of low-dose ASA [112,113]. A reduced risk of melanoma among ASA users was also observed in the WHI Observational Study, a large cohort study including 59,806 postmenopausal women [115]. In this study, the risk of melanoma was 21 percent lower in women using ASA than in nonusers (HR 0.79, 95% CI 0.63-0.98) [115]. In contrast, another large cohort study including 63,809 patients did not find any association between NSAID use and melanoma risk [116].

Lipid-lowering agents — Lipid-lowering drugs, such as statins and fibrates, have also been evaluated. Three systematic reviews and meta-analyses of randomized trials of statins and fibrates for the prevention of heart disease were unable to identify a statistically significant effect of lipid-lowering drugs on melanoma risk [95,117,118].

Other promising agents — In a randomized phase 3 trial, the use of oral nicotinamide (vitamin B3) 500 mg twice daily for 12 months resulted in a 13 percent reduction of actinic keratoses (p = 0.001) and a 23 percent reduction of NMSCs (p = 0.02) [119]. However, the study was not adequately powered to assess an effect on melanoma and was conducted over a relatively short period of time, making it difficult to determine whether nicotinamide might be a good candidate for melanoma prevention. Given the shared UV radiation-related etiology of these tumors, further investigation appears warranted.

Other candidate agents for therapeutic prevention of melanoma include pigmentation enhancers, DNA repair enzymes, additional vitamins and minerals, and phytochemicals (ie, plant-derived, biologically active compounds) [120].

PUBLIC HEALTH MEASURES — A variety of public health measures have been implemented in an attempt to reduce the risk of skin cancers, including melanoma. Examples include government-sponsored efforts, such as the SunSmart campaign in Australia and the Environmental Protection Agency's SunWise Program in the United States. The media is another outlet for increasing awareness of sun protection; some television stations and newspapers notify the public of days on which the risk of high ultraviolet (UV) exposure is elevated. However, no studies have directly linked the implementation of public health programs to a reduction in melanoma incidence.

Clinician efforts to educate patients on protection from UV light exposure may influence patient behavior. A 2011 systematic review performed for the US Preventive Services Task Force (USPSTF) found that patient counseling with tailored feedback in the primary care setting was associated with modest improvement in sun-protective practices and reduced indoor tanning [121]. A 2018 update of this review confirmed small to moderate effects of behavioral interventions on increased sun protection behaviors in all age groups, with more consistent effects seen in children and adolescents [35]. Based on evidence of benefit of behavioral counseling interventions on children's parents, adolescents, and young adults, the USPSTF recommends counseling young adults, adolescents, children, and parents of young children about minimizing exposure to UV radiation for persons aged 6 months to 24 years with fair skin type to reduce their risk of skin cancer [122]. Based on evidence of the limited net benefit of counseling all adults older than 24 years, the USPSTF also recommends that clinicians consider selectively offering counseling to adults older than 24 years with fair skin type based on their risk factors.

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Melanoma screening, prevention, diagnosis, and management".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topics (see "Patient education: Sunburn (The Basics)")

Beyond the Basics topics (see "Patient education: Sunburn (Beyond the Basics)" and "Patient education: Sunburn prevention (Beyond the Basics)")

SUMMARY AND RECOMMENDATIONS

Reducing exposure to ultraviolet radiation – Ultraviolet (UV) radiation has been implicated as a risk factor for melanoma. Although studies of the impact of UV-protective measures on melanoma incidence are limited, interventions to reduce individual exposure to UV light are recommended, especially in people with lightly pigmented skin. (See 'Ultraviolet radiation' above.)

Shade structures, sun-protective clothing, sunscreen, and other measures can provide sun protection. Individuals at increased risk of melanoma and individuals highly exposed to sunlight should apply a broad-spectrum sunscreen with a sun protection factor (SPF) of 15 or higher daily and thoroughly before going out during daylight hours. Because of inconsistent application, the American Academy of Dermatology recommends the use of a broad-spectrum sunscreen with an SPF of at least 30 before sun exposure. (See 'Sun protection' above and "Selection of sunscreen and sun-protective measures".)

Avoiding indoor tanning – Tanning bed use is associated with an increased risk for melanoma and should be avoided. Additional studies are necessary to explore whether some individuals develop a biochemical addiction to tanning. (See 'Tanning bed use' above.)

Chemoprevention – There is limited and conflicting evidence that vitamin D, nonsteroidal anti-inflammatory agents, or lipid-lowering agents have a chemopreventive effect on melanoma. Other agents are under investigation for therapeutic prevention of melanoma and nonmelanoma skin cancer. (See 'Chemoprevention' above.)

Public health measures – A variety of public health programs, most notably the Australian SunSmart campaign, have resulted in improved sun protection as well as stabilization of incidence rates that were increasing precipitously in earlier years. The US Preventive Services Task Force (USPSTF) recommends counseling young adults, adolescents, children, and parents of young children about minimizing exposure to UV radiation for persons aged 6 months to 24 years with fair skin type to reduce their risk of skin cancer and selectively offering this counseling to people over the age of 24 years with fair skin type based on their risk factors. (See 'Public health measures' above.)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69:7.
  2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893.
  3. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827.
  4. Armstrong BK, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res 1993; 3:395.
  5. Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999; 340:1341.
  6. Guy GP Jr, Thomas CC, Thompson T, et al. Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030. MMWR Morb Mortal Wkly Rep 2015; 64:591.
  7. Aitken JF, Youlden DR, Baade PD, et al. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014. Int J Cancer 2018; 142:1528.
  8. Tabbakh T, Volkov A, Wakefield M, Dobbinson S. Implementation of the SunSmart program and population sun protection behaviour in Melbourne, Australia: Results from cross-sectional summer surveys from 1987 to 2017. PLoS Med 2019; 16:e1002932.
  9. Holman DM, Freeman MB, Shoemaker ML. Trends in Melanoma Incidence Among Non-Hispanic Whites in the United States, 2005 to 2014. JAMA Dermatol 2018; 154:361.
  10. Guy GP Jr, Berkowitz Z, Everett Jones S, et al. Prevalence of Indoor Tanning and Association With Sunburn Among Youth in the United States. JAMA Dermatol 2017; 153:387.
  11. International Agency for Research on Cancer. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans. Vol 100. Geneva, Switzerland: World Health Organization Press; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100D/mono100D.pdf (Accessed on March 21, 2018).
  12. MacLennan R, Green AC, McLeod GR, Martin NG. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 1992; 84:1427.
  13. Arnold M, de Vries E, Whiteman DC, et al. Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012. Int J Cancer 2018; 143:1305.
  14. World Health Organization. Ultraviolet radiation. https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation (Accessed on May 12, 2023).
  15. Battistutta D, Palmer J, Walters M, et al. Incidence of familial melanoma and MLM2 gene. Lancet 1994; 344:1607.
  16. Atillasoy ES, Seykora JT, Soballe PW, et al. UVB induces atypical melanocytic lesions and melanoma in human skin. Am J Pathol 1998; 152:1179.
  17. Stern RS, PUVA Follow up Study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44:755.
  18. Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336:1041.
  19. Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 2012; 345:e4757.
  20. Burgard B, Schöpe J, Holzschuh I, et al. Solarium Use and Risk for Malignant Melanoma: Meta-analysis and Evidence-based Medicine Systematic Review. Anticancer Res 2018; 38:1187.
  21. Colantonio S, Bracken MB, Beecker J. The association of indoor tanning and melanoma in adults: systematic review and meta-analysis. J Am Acad Dermatol 2014; 70:847.
  22. Ghiasvand R, Rueegg CS, Weiderpass E, et al. Indoor Tanning and Melanoma Risk: Long-Term Evidence From a Prospective Population-Based Cohort Study. Am J Epidemiol 2017; 185:147.
  23. Whiteman DC, Watt P, Purdie DM, et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95:806.
  24. Young AR. The sunburn cell. Photodermatol 1987; 4:127.
  25. Wang SQ, Setlow R, Berwick M, et al. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001; 44:837.
  26. Nelemans PJ, Groenendal H, Kiemeney LA, et al. Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals. Environ Health Perspect 1993; 101:252.
  27. Elwood JM, Gallagher RP, Hill GB, Pearson JC. Cutaneous melanoma in relation to intermittent and constant sun exposure--the Western Canada Melanoma Study. Int J Cancer 1985; 35:427.
  28. Weinstock MA. Controversies in the role of sunlight in the pathogenesis of cutaneous melanoma. Photochem Photobiol 1996; 63:406.
  29. Cooke KR, Fraser J. Migration and death from malignant melanoma. Int J Cancer 1985; 36:175.
  30. Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst 1984; 73:75.
  31. Tadokoro T, Kobayashi N, Zmudzka BZ, et al. UV-induced DNA damage and melanin content in human skin differing in racial/ethnic origin. FASEB J 2003; 17:1177.
  32. Lopes FCPS, Sleiman MG, Sebastian K, et al. UV Exposure and the Risk of Cutaneous Melanoma in Skin of Color: A Systematic Review. JAMA Dermatol 2021; 157:213.
  33. Kolitz E, Lopes FCPS, Arffa M, et al. UV Exposure and the Risk of Keratinocyte Carcinoma in Skin of Color: A Systematic Review. JAMA Dermatol 2022; 158:542.
  34. US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2018; 319:1134.
  35. Henrikson NB, Morrison CC, Blasi PR, et al. Behavioral Counseling for Skin Cancer Prevention: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 319:1143.
  36. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011; 29:257.
  37. van der Pols JC, Williams GM, Pandeya N, et al. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 2006; 15:2546.
  38. Ghiasvand R, Weiderpass E, Green AC, et al. Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study. J Clin Oncol 2016; 34:3976.
  39. Watts CG, Drummond M, Goumas C, et al. Sunscreen Use and Melanoma Risk Among Young Australian Adults. JAMA Dermatol 2018; 154:1001.
  40. Tuchinda C, Srivannaboon S, Lim HW. Photoprotection by window glass, automobile glass, and sunglasses. J Am Acad Dermatol 2006; 54:845.
  41. Draelos ZD. The multifunctional value of sunscreen-containing cosmetics. Skin Therapy Lett 2011; 16:1.
  42. Harrison SL, Buettner PG, Maclennan R. The North Queensland "Sun-Safe Clothing" study: design and baseline results of a randomized trial to determine the effectiveness of sun-protective clothing in preventing melanocytic nevi. Am J Epidemiol 2005; 161:536.
  43. Gallagher RP, Rivers JK, Lee TK, et al. Broad-spectrum sunscreen use and the development of new nevi in white children: A randomized controlled trial. JAMA 2000; 283:2955.
  44. de Maleissye MF, Beauchet A, Saiag P, et al. Sunscreen use and melanocytic nevi in children: a systematic review. Pediatr Dermatol 2013; 30:51.
  45. English DR, Milne E, Jacoby P, et al. The effect of a school-based sun protection intervention on the development of melanocytic nevi in children: 6-year follow-up. Cancer Epidemiol Biomarkers Prev 2005; 14:977.
  46. Bauer J, Büttner P, Wiecker TS, et al. Effect of sunscreen and clothing on the number of melanocytic nevi in 1,812 German children attending day care. Am J Epidemiol 2005; 161:620.
  47. National Institute for Health and Clinical Excellence. PH32 skin cancer prevention: Information, resources and environmental changes: Guidance. http://guidance.nice.org.uk/PH32/Guidance/pdf/English (Accessed on April 04, 2011).
  48. www.cancer.org.au/cancersmartlifestyle/SunSmart/Preventingskincancer.htm (Accessed on April 04, 2011).
  49. National Council on Skin Cancer Prevention. www.skincancerprevention.org (Accessed on January 25, 2007).
  50. Harmful effects of ultraviolet radiation. Council on Scientific Affairs. JAMA 1989; 262:380.
  51. Goldsmith L, Koh HK, Bewerse B, et al. Proceedings from the national conference to develop a national skin cancer agenda. American Academy of Dermatology and Centers for Disease Control and Prevention, April 8-10, 1995. J Am Acad Dermatol 1996; 34:822.
  52. Balk SJ, Council on Environmental Health, Section on Dermatology. Ultraviolet radiation: a hazard to children and adolescents. Pediatrics 2011; 127:e791.
  53. Council on Environmental Health, Section on Dermatology, Balk SJ. Ultraviolet radiation: a hazard to children and adolescents. Pediatrics 2011; 127:588.
  54. The National Council on Skin Cancer Prevention. Sun safety. https://skincancerprevention.org/learning/sun-safety/ (Accessed on May 13, 2021).
  55. The National Council on Skin Cancer Prevention. Sunscreen. https://skincancerprevention.org/learning/sunscreen/ (Accessed on May 13, 2021).
  56. American Academy of Dermatology. Sunscreen FAQs. https://www.aad.org/public/everyday-care/sun-protection/sunscreen-patients/sunscreen-faqs (Accessed on April 20, 2021).
  57. Holman DM, Ding H, Guy GP Jr, et al. Prevalence of Sun Protection Use and Sunburn and Association of Demographic and Behaviorial Characteristics With Sunburn Among US Adults. JAMA Dermatol 2018; 154:561.
  58. Ghiasvand R, Lund E, Edvardsen K, et al. Prevalence and trends of sunscreen use and sunburn among Norwegian women. Br J Dermatol 2015; 172:475.
  59. Coups EJ, Manne SL, Heckman CJ. Multiple skin cancer risk behaviors in the U.S. population. Am J Prev Med 2008; 34:87.
  60. Holman DM, Berkowitz Z, Guy GP Jr, et al. The association between demographic and behavioral characteristics and sunburn among U.S. adults - National Health Interview Survey, 2010. Prev Med 2014; 63:6.
  61. Geller AC, Colditz G, Oliveria S, et al. Use of sunscreen, sunburning rates, and tanning bed use among more than 10 000 US children and adolescents. Pediatrics 2002; 109:1009.
  62. Koh HK, Geller AC. Public health interventions for melanoma. Prevention, early detection, and education. Hematol Oncol Clin North Am 1998; 12:903.
  63. Miller DR, Geller AC, Wood MC, et al. The Falmouth Safe Skin Project: evaluation of a community program to promote sun protection in youth. Health Educ Behav 1999; 26:369.
  64. Benjes LS, Brooks DR, Zhang Z, et al. Changing patterns of sun protection between the first and second summers for very young children. Arch Dermatol 2004; 140:925.
  65. Bränström R, Kristjansson S, Dal H, Rodvall Y. Sun exposure and sunburn among Swedish toddlers. Eur J Cancer 2006; 42:1441.
  66. McGee R, Williams S. Adolescence and sun protection. N Z Med J 1992; 105:401.
  67. Dusza SW, Halpern AC, Satagopan JM, et al. Prospective study of sunburn and sun behavior patterns during adolescence. Pediatrics 2012; 129:309.
  68. LeFevre ML, LeFevre NM. Vitamin D Screening and Supplementation in Community-Dwelling Adults: Common Questions and Answers. Am Fam Physician 2018; 97:254.
  69. Egan KM, Sosman JA, Blot WJ. Sunlight and reduced risk of cancer: is the real story vitamin D? J Natl Cancer Inst 2005; 97:161.
  70. Lim HW, Gilchrest BA, Cooper KD, et al. Sunlight, tanning booths, and vitamin D. J Am Acad Dermatol 2005; 52:868.
  71. International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer 2007; 120:1116.
  72. Autier P, Boyle P. Artificial ultraviolet sources and skin cancers: rationale for restricting access to sunbed use before 18 years of age. Nat Clin Pract Oncol 2008; 5:178.
  73. Lazovich D, Vogel RI, Berwick M, et al. Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev 2010; 19:1557.
  74. Lazovich D, Isaksson Vogel R, Weinstock MA, et al. Association Between Indoor Tanning and Melanoma in Younger Men and Women. JAMA Dermatol 2016; 152:268.
  75. The European Commission. Joint action on sunbeds 2008-2009. www.ec.europa.eu/consumers/citizen/my_safety/sunbeds/sunbeds_report_2008-2009_en.pdf (Accessed on May 25, 2016).
  76. Government of British Columbia. Tanning beds. www.health.gov.bc.ca/protect/ehp-tanning-beds.html (Accessed on April 17, 2013).
  77. Government of South Australia. Radiation protection and control (cosmetic tanning units) regulations 2008. www.legislation.sa.gov.au/LZ/C/R/RADIATION%20PROTECTION%20AND%20CONTROL%20%28COSMETIC%20TANNING%20UNITS%29%20REGULATIONS%202008.aspx (Accessed on April 17, 2013).
  78. National Conference of State Legislatures. Indoor tanning restrictions for minors: A state-by-state comparison. www.ncsl.org/research/health/indoor-tanning-restrictions.aspx (Accessed on March 27, 2018).
  79. Grewal SK, Haas AF, Pletcher MJ, Resneck JS Jr. Compliance by California tanning facilities with the nation's first statewide ban on use before the age of 18 years. J Am Acad Dermatol 2013; 69:883.
  80. Choy CC, Cartmel B, Clare RA, Ferrucci LM. Compliance with indoor tanning bans for minors among businesses in the USA. Transl Behav Med 2017; 7:637.
  81. FDA to require warnings on sunlamp products. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm399222.htm (Accessed on February 11, 2015).
  82. Feldman SR, Liguori A, Kucenic M, et al. Ultraviolet exposure is a reinforcing stimulus in frequent indoor tanners. J Am Acad Dermatol 2004; 51:45.
  83. Kaur M, Feldman SR, Liguori A, Fleischer AB Jr. Indoor tanning relieves pain. Photodermatol Photoimmunol Photomed 2005; 21:278.
  84. Taylor SL, Kaur M, LoSicco K, et al. Pilot study of the effect of ultraviolet light on pain and mood in fibromyalgia syndrome. J Altern Complement Med 2009; 15:15.
  85. Hillhouse J, Stapleton J, Turrisi R. Association of frequent indoor UV tanning with seasonal affective disorder. Arch Dermatol 2005; 141:1465.
  86. Nolan BV, Taylor SL, Liguori A, Feldman SR. Tanning as an addictive behavior: a literature review. Photodermatol Photoimmunol Photomed 2009; 25:12.
  87. Kourosh AS, Harrington CR, Adinoff B. Tanning as a behavioral addiction. Am J Drug Alcohol Abuse 2010; 36:284.
  88. Harrington CR, Beswick TC, Leitenberger J, et al. Addictive-like behaviours to ultraviolet light among frequent indoor tanners. Clin Exp Dermatol 2011; 36:33.
  89. Petit A, Lejoyeux M, Reynaud M, Karila L. Excessive indoor tanning as a behavioral addiction: a literature review. Curr Pharm Des 2014; 20:4070.
  90. Miller KA, Piombo SE, Cho J, et al. Prevalence of Tanning Addiction and Behavioral Health Conditions among Ethnically and Racially Diverse Adolescents. J Invest Dermatol 2018; 138:1511.
  91. Kaur M, Liguori A, Lang W, et al. Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners. J Am Acad Dermatol 2006; 54:709.
  92. Gambichler T, Bader A, Vojvodic M, et al. Plasma levels of opioid peptides after sunbed exposures. Br J Dermatol 2002; 147:1207.
  93. Demierre MF, Merlino G. Chemoprevention of melanoma. Curr Oncol Rep 2004; 6:406.
  94. Demierre MF, Nathanson L. Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol 2003; 21:158.
  95. Freeman SR, Drake AL, Heilig LF, et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst 2006; 98:1538.
  96. Jeter JM, Bowles TL, Curiel-Lewandrowski C, et al. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer 2019; 125:18.
  97. Moan J, Porojnicu AC, Dahlback A, Setlow RB. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc Natl Acad Sci U S A 2008; 105:668.
  98. Berwick M, Armstrong BK, Ben-Porat L, et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 2005; 97:195.
  99. Caini S, Boniol M, Tosti G, et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis. Eur J Cancer 2014; 50:2649.
  100. Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981; 108:1083.
  101. Evans SR, Houghton AM, Schumaker L, et al. Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J Surg Res 1996; 61:127.
  102. Reichrath J, Rech M, Moeini M, et al. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells. Cancer Biol Ther 2007; 6:48.
  103. Seifert M, Rech M, Meineke V, et al. Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro. J Steroid Biochem Mol Biol 2004; 89-90:375.
  104. Eisman JA, Barkla DH, Tutton PJ. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res 1987; 47:21.
  105. Yudoh K, Matsuno H, Kimura T. 1alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J Lab Clin Med 1999; 133:120.
  106. Asgari MM, Maruti SS, Kushi LH, White E. A cohort study of vitamin D intake and melanoma risk. J Invest Dermatol 2009; 129:1675.
  107. Weinstock MA, Stampfer MJ, Lew RA, et al. Case-control study of melanoma and dietary vitamin D: implications for advocacy of sun protection and sunscreen use. J Invest Dermatol 1992; 98:809.
  108. Millen AE, Tucker MA, Hartge P, et al. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 2004; 13:1042.
  109. Veierød MB, Thelle DS, Laake P. Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. Int J Cancer 1997; 71:600.
  110. Tang JY, Fu T, Leblanc E, et al. Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. J Clin Oncol 2011; 29:3078.
  111. Famenini S, Young LC. Aspirin use and melanoma risk: a review of the literature. J Am Acad Dermatol 2014; 70:187.
  112. Curiel-Lewandrowski C, Nijsten T, Gomez ML, et al. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol 2011; 131:1460.
  113. Joosse A, Koomen ER, Casparie MK, et al. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol 2009; 129:2620.
  114. Johannesdottir SA, Chang ET, Mehnert F, et al. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 2012; 118:4768.
  115. Gamba CA, Swetter SM, Stefanick ML, et al. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative. Cancer 2013; 119:1562.
  116. Asgari MM, Maruti SS, White E. A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. J Natl Cancer Inst 2008; 100:967.
  117. Bonovas S, Nikolopoulos G, Filioussi K, et al. Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. Eur J Epidemiol 2010; 25:29.
  118. Li X, Wu XB, Chen Q. Statin use is not associated with reduced risk of skin cancer: a meta-analysis. Br J Cancer 2014; 110:802.
  119. Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med 2015; 373:1618.
  120. Minocha R, Damian DL, Halliday GM. Melanoma and nonmelanoma skin cancer chemoprevention: A role for nicotinamide? Photodermatol Photoimmunol Photomed 2018; 34:5.
  121. Lin JS, Eder M, Weinmann S. Behavioral counseling to prevent skin cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 154:190.
  122. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2023; 329:1290.
Topic 4842 Version 34.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟